REPROCELL News

A recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals. This is the first time that drug absorption has been estimated using inflamed GI tissue from this patient group. A similar study, performed by Keio University, estimated drug absorption in healthy areas of GI tissue from ulcerative colitis (UC) donors.

Continue reading →

Drug Discovery news, Human Tissues, Ussing Chamber, IBD Research


Glasgow, UK: REPROCELL (Biopta) today announced the successful publication of a novel study in  pharmacology and genomics to improve strategies for the development of precision medicines. The study – performed in collaboration with the NHS, academia and Scottish companies Fios Genomics, Systemic, and Aridhia – used human living lung tissue from Chronic Obstructive Pulmonary Disease (COPD) donors to explain inter-patient variation in drug efficacy.

Continue reading →

Human Tissues, Precision Medicine, Pharmacogenomics


Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.

Continue reading →

Drug Discovery news, Human Tissues, MEA testing, Cardiac Research


REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.

Continue reading →

Drug Discovery news, Human Tissues, Primary Cells


REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.

Continue reading →

Human Tissues, Stem Cells, Human Genome Sequencing, Bioinformatics, Global Expertise


REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday, at https://www.dur.ac.uk/news/newsitem/?itemno=33385

Continue reading →

Drug Discovery news, Human Tissues, 3D Cell Model, Bio-engineered Tissue Models